Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis (WBI-1001-101)
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||A Randomized, Double-Blind Phase I Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Psoriasis.|
- Evaluate safety and tolerability of topically applied WBI-1001 cream, and to assess the pharmacokinetics based on plasma concentrations [ Time Frame: 35 days ]
- Obtain initial evaluation of efficacy of topically applied WBI-1001 cream in patients with mild to moderate psoriasis. [ Time Frame: 35 days ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||July 2007|
|Study Completion Date:||June 2008|
|Primary Completion Date:||April 2008 (Final data collection date for primary outcome measure)|
Patients initiated screening within 4 weeks of commencing study treatment. Based on progression of the study, at day 0 patients were assigned to one of six treatment Cohorts. Patients were randomized to treat all areas except the face, scalp, groin and genital areas. Patients in Cohort 1 were treated on one side with a thin layer of active cream and the other with placebo; in the absence of significant AEs by 14 days after the last treatment in the Cohort escalation to the next Cohort was allowed, and each Cohort respectively.
During the treatment period patients visited the study centre weekly for safety, tolerability and efficacy assessment. On these study visit days blood draws were done between 7.00 and 10.00am prior to that morning's application of cream.
The study enrolled healthy male and female patients aged 18-65 y.o. with clinical diagnosis of stable plaque psoriasis for >months affecting a maximum of 6% of BSA with a minimum of 0.5% BSA on each side of the body and a minimum of one plaque at least 2x2 cm on each side excluding elbow and knee.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00830817
|Innovaderm Research inc.|
|Montreal, Quebec, Canada, H2K 4L5|
|Study Chair:||John m Webster, PhD, D.Sc.||Welichem Biotech Inc.|
|Study Director:||Liren Tang, Ph.D||Welichem Biotech Inc.|